The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer

Monday, May 14, 2012

Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer09:00 EDT Monday, May 14, 2012PARAMOUNT Study One of More than 25 Lilly Oncology Studies at Key Cancer MeetingINDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 ? 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA® (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer. Lilly presented progression-free survival data from PARAMOUNT at the 2011 ASCO meeting.Other Lilly Oncology research being presented at ASCO will include additional clinical data on ALIMTA. ALIMTA Studies: Abstract # LBA7507: Oral Abstract Session: Monday, June 4, 2012; 5:15 PM ? 5:30 PM PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed plus best supportive care versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer Author/Speaker: Luis Paz-Ares Location: E Hall D2Abstract # 7002: Oral Abstract Session: Monday, June 4, 2012; 8:30 AM ? 8:45 AM Phase II Study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIA/B non-small cell lung cancer Author/Speaker: Hak Choy Location: E Hall D2P-LLYThis press release contains forward-looking statements about the potential of ALIMTA and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )SOURCE Eli Lilly and CompanyFor further information: Amy Sousa (Lilly), Office: +1-317-276-8478, Mobile: +1-317-997-1481; Neil Hochman (TogoRun), Office: +1-212-453-2067, Mobile: +1-516-784-9089